## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.1% below STRENGTH zone (4.0-10.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (50% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($51.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY**
- Source: ts2.tech | 20251231T045701 | Neutral | Relevance: 100%
- Bristol-Myers Squibb shares closed slightly higher on Tuesday amidst thin, year-end trading on Wall Street. Investors are looking ahead to the company's early-January dividend record date and its upcoming quarterly earnings report scheduled for February 5, 2026. The stock's performance reflects a modest gain as the broader market saw slight declines, with analysts noting the convergence of growth rates between technology and other sectors in the coming year.

**2. Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?**
- Source: Benzinga | 20260102T180735 | Somewhat-Bullish | Relevance: 100%
- Deep-pocketed investors are showing significant options activity for Bristol-Myers Squibb (NYSE: BMY), with a divided sentiment but a notable bullish leaning. Out of 9 extraordinary options activities, 55% were bullish calls and 22% bearish puts, suggesting a potential price target between $25.0 and $52.5 in the coming months. This unusual activity, combined with recent analyst upgrades and downgrades, indicates that something significant might be on the horizon for the pharmaceutical company.

**3. A different kind of treatment for schizophrenia**
- Source: USA Today | 20260101T140746 | Bullish | Relevance: 100%
- This article discusses schizophrenia, its varied symptoms, and introduces COBENFY™ (xanomeline and trospium chloride), a new treatment option from Bristol Myers Squibb. Dr. Gil Hoftman explains how COBENFY works differently from traditional antipsychotics by activating muscarinic acetylcholine receptors, potentially improving positive, negative, and cognitive symptoms. The piece also details important safety information and patient support available for COBENFY users.

**4. Avaii Wealth Management LLC Has $676,000 Stock Holdings in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20260101T080823 | Somewhat-Bullish | Relevance: 100%
- Avaii Wealth Management LLC significantly reduced its stake in Bristol Myers Squibb (BMY) by 81.7% in Q3, selling 66,729 shares but still holding 14,992 shares valued at $676,000. Despite this, other institutional investors like Allspring Global increased their positions, with hedge funds and institutions collectively owning 76.41% of BMY. Bristol Myers Squibb reported strong Q3 EPS, provided optimistic FY2025 guidance, and raised its quarterly dividend to $0.63, with analysts maintaining a consensus "Hold" rating and a $54.62 price target.

**5. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)**
- Source: MarketBeat | 20251231T213741 | Bullish | Relevance: 100%
- Bristol Myers Squibb (NYSE:BMY) experienced unusually high options trading volume on Wednesday, with traders acquiring 180,226 call options, representing a 304% increase over typical volume. This surge in call options indicates elevated bullish interest or hedging activity. The company recently reported solid quarterly results, beating EPS and revenue expectations, provided positive FY2025 guidance, and increased its quarterly dividend to $0.63, yielding approximately 4.7%.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (4 raises, avg +10%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $108.8B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.9 |
| Current P/E | 8.2 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.4% to 2.1% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. Volume at 50% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.10% (CS: 72) | Neutral |
| RSI_14 | 59.0 | Neutral |
| MACD Histogram | -0.22 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.085x | Above |
| vs SMA200 | 1.102x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $53.46
- **Stop Loss:** $51.40 (3.9% risk)
- **Target:** $55.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 699
- **Position Value:** $37,368.54
- **Portfolio %:** 37.37%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*